DecisionLine conducts Phase I studies focusing on central nervous system drugs and also does human abuse liability studies and abuse potential and risk mitigation assessments, Kendle said in a news release. The company operates an 82-bed, 36,000-square-foot facility for drug studies in Toronto, and has 110 full-time and 130 part-time employees.
Drs. Edward Sellers and Myroslava Romach, co-founders of DecisionLine, will remain with Kendle. Sellers will serve as general manager, early-phase Toronto and senior scientist; and Romach will become head of clinical operations and medical affairs, early-phase, Toronto, and senior scientist.
"With Phase I growth expected to outpace the broader outsourcing market at approximately 15 percent annually, early phase development remains an important need for our customers and an area of significant growth opportunity for Kendle," said President Simon Higginbotham in the release.
Kendle's early-phase operations include a clinical pharmacology unit in Utrecht, the Netherlands, where it has a 48-bed facility, and in Morgantown, W.Va., where it has a 118-bed bioequivalance facility.
Kendle International (NASDAQ: KNDL), headquartered in Cincinnati, is a clinical research organization with operations worldwide.
